Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Transcenta Holding's Total Assets for the quarter that ended in Dec. 2025 was HK$1,021.69 Mil.
During the past 12 months, Transcenta Holding's average Total Assets Growth Rate was -8.60% per year.
During the past 3 years, the average Total Assets Growth Rate was -10.10% per year.
During the past 5 years, the average Total Assets Growth Rate was -9.00% per year.
During the past 7 years, Transcenta Holding's highest 3-Year average Total Assets Growth Rate was 3.90%. The lowest was -12.10%. And the median was -8.10%.
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Transcenta Holding's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Transcenta Holding Total Assets Related Terms
Transcenta Holding Total Assets Historical Data
* Premium members only.
The historical data trend for Transcenta Holding's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Transcenta Holding's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Transcenta Holding (HKSE:06628) has a Total Assets of HK$1,021.69 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Transcenta Holding and its competitors.
Is Transcenta Holding's Total Assets too high?
Transcenta Holding's current Total Assets is HK$1,021.69 Mil. Overall, Transcenta Holding has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Transcenta Holding's Total Assets compare to VRTX and REGN?
Transcenta Holding's Total Assets of HK$1,021.69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Transcenta Holding and its competitors. Transcenta Holding's current Total Assets is HK$1,021.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transcenta Holding stock overvalued right now?
Based on GuruFocus' analysis, Transcenta Holding (HKSE:06628) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.29, compared to a current price of HK$0.91 — trading 213.8% above its estimated fair value. The current Total Assets is HK$1,021.69 Mil. Transcenta Holding's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Transcenta Holding (HKSE:06628), the current Total Assets is HK$1,021.69 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Transcenta Holding (HKSE:06628) Overvalued in 2026?
Based on GuruFocus' analysis, Transcenta Holding stock appears to be overvalued.
The current stock price of HK$0.91 is trading 213.8% above its estimated GF Value™ of HK$0.29.
GuruFocus considers Transcenta Holding to be Significantly Overvalued.
Key valuation signals for HKSE:06628:
Total Assets: HK$1,021.69 Mil
GF Value™: HK$0.29 vs. price of HK$0.91 (213.8% above fair value)
No single metric tells the full story. See the HKSE:06628 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Transcenta Holding Ltd is a clinical-stage biopharmaceutical company with fully integrated capabilities across discovery, research, clinical development, and manufacturing, uniquely positioned to advance high-impact biologic innovations with commercial potential. The company's asset, Osemitamab (TST001), is a anti-Claudin18.2 monoclonal antibody currently advancing toward late-stage development. It is building a differentiated pipeline spanning oncology, osteoporosis, kidney disease, and autoimmune disorders. It operates in a single segment and geographically its operations are spread across Chinese mainland, United States of America, and Others with Chinese Mainland deriving the majority of revenue.
40GF Score
Get the complete analysis for HKSE:06628
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06628 has been successfully added to your 
